DOCSLIB.ORG

RMM Art 2.Indd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Modern Medicine | 2017, Vol. 24, No. 1 REVIEWS Pharmacodynamics of Serotonin. Emphasis on 5HT-3 Antagonists and SSRI Medication (II) Mihnea Costescu1, Horia Paunescu1, Sorina Vasile2, Aurelian Zugravu1, Oana Andreia Coman1, Ion Fulga1 Abstract This paper is a specialized literature review of the pharmacology of serotonin, that focuses on pharmacodyna- mics. The main aspects discussed here are the metabolism and transport of serotonin, along with the structure and functions of 5-HT receptors and their clinical implications. We also included the substances that influence the serotonin neurotransmission and the autacoid function, which may be prove useful in treating various disorders. In this second part of the review, we present the types of 5-HT receptors (5-HT4, 5-HT5, 5-HT6, 5-HT7), along with the tendencies and prospects in influencing serotonin transporter (SERT) through selective serotonin reuptake in- hibitors (SSRIs). In order to achieve better safety and effectiveness of antidepressant therapy, recent research is studying substances that not only target SERT, but can also act on certain serotonergic receptors. Keywords: serotonin, 5-HT receptors, cisapride, selective serotonin reuptake inhibitors (SSRI), tedatioxetine, vortio- xetine, vilazodone, amitifadine Rezumat Acest articol reprezintă o recenzie de literatură privind farmacologia și, în special, farmacodinamia serotoninei. Principalele aspecte abordate sunt metabolizarea, transportul serotoninei, precum și structura, funcţiile recepto- rilor 5-HT și implicaţiile clinice ale acestora. S-au inclus date despre substanţe care influenţează neurotransmisia serotoninergică și funcţia de autacoid a serotoninei, care se pot dovedi utile în tratamentul anumitor afecţiuni. În această a doua parte a recenziei, sunt prezentate celelalte tipuri de receptori serotoninergici (5-HT4, 5-HT5, 5-HT6, 5-HT7), alături de tendinţele și perspectivele actuale în influenţarea transportorului serotoninei prin inhibitori selec- tivi ai recaptării serotoninei. Pentru a obţine o mai mare siguranţă și efi cacitate a tratamentului antidepresiv, studii recente au descris substanţe care, pe lângă efectul asupra transportorului serotoninei, acţionează direct și asupra unor anumiţi receptori serotoninergici. Cuvinte cheie: serotonină, receptori serotoninergici, cisapridă, inhibitori selectivi ai recaptării serotoninei, tedatioxe- tină, vortioxetină, vilazodonă, amitifadină SEROTONERGIC RECEPTORS AND It has two isoforms (5-HT4S and 5-HT4L), diff ering in the length and sequence of their C-termini1. 5-HT THEIR IMPLICATIONS IN THERAPY 4 are present both in the central nervous system and pe- (PART II) ripheral tissues; in the brain, are found mostly in basal 2 5-HT4 receptors are a G-protein-coupled family of re- ganglia and the hippocampus . In the periphery, 5HT4 ceptors coupled with Gs protein that stimulates the pro- play an important role in the functioning of gastroin- duction of the intracellular signaling molecule cAMP. testinal tract, urinary bladder, heart and adrenal gland. 1 Department of Pharmacology and Pharmacotherapy, "Carol Da- Corresponding author: vila" University of Medicine and Pharmacy, Bucharest, Romania Horia Paunescu 2 Clinical Pharmacology, Bucharest, Romania Faculty of Medicine, 8th Eroilor Sanitari Boulevard, 5th District, Bucharest, Romania. E-mail: [email protected] 5 Mihnea Costescu et al. Gastrointestinal 5-HT4 receptors potentiate peristalsis, selective agonists or antagonists are commercially avai- and electrolyte secretion. In the urinary bladder, acti- lable for the 5-HT5A receptor, but extensive research is 13 vation of 5-HT4 receptors modulates cholinergic and being done in this direction . purinergic transmission. Stimulation of atrial 5-HT4 Th e 5-HT6 receptors are Gs coupled proteins and receptors produces tachycardia and arrhythmias. In the are present in the brain, most prominently in the ca- adrenal gland, activation of 5-HT4 receptors releases udate nucleus, but also in striatum, olfactory tubercle, cortisol, aldosterone and corticosterone3. nucleus accumbens and hippocampus14,15. Because of Cisapride is a 5-HT4 agonist that increases moti- its abundance in limbic and cortical regions, it has been lity of the upper gastrointestinal tract. It was widely suggested that 5-HT6 receptors play a role in regula- prescribed as a prokinetic agent. Cisapride was wi- ting glutamatergic and cholinergic neuronal activity thdrawn in 2000 because of reports of the side-eff ect and are involved in the cognition, feeding and, possi- long QT syndrome, which may cause arrhythmias, e.g. bly, aff ective state and seizures16. Indeed, studies with 4 torsade des pointes . Other 5-HT4 agonists are suppo- 5-HT6 receptor antagonists have shown encouraging sed to be antidepressants with early onset of eff ects5. results in improving cognitive performance in patients 17 Cisapride's mechanism of action include increasing the with Alzheimer's . 5-HT6 receptor antagonists po- phosphorylation of the CREB protein, desensitization tentiate the antidepressant eff ects of SERT inhibition. of 5-HT1A autoreceptors and promoting neurogenesis Also, it has been suggested that co-administration of a 6 in the hippocampus . lower dose of an antidepressant with a 5-HT6 receptor Because of their properties, 5-HT4 receptor agonists antagonist might speed up the onset of action and re- 5 and antagonists may also be useful in the treatment duce the side-eff ects . Stimulation of 5-HT6 receptors of cardiac arrhythmias, urinary incontinence, irritable might play a role in some of the behavioral and chemi- bowel syndrome and gastroparesis3. However, because cal eff ects of antidepressants such as fl uoxetine18. of the severity of the adverse eff ects, extensive research Th e 5-HT7 receptors are receptors coupled with 19 is being done in fi nding a safe new-generation 5-HT4 protein Gs protein . Th e 5-HT7 receptors are found receptor ligands that can be used in medical treat- especially in the brain, the gastrointestinal tract, in ments7. blood vessels andin the intestinal immune cells20. Th e- For the clinical treatment of IBS-C (irritable bowel re is also evidence that 5-HT signaling (including syndrome with constipation predominance) 5-HT4 re- 5-HT7) plays an important role in various gut disorders ceptor agonists are sometimes employed. 5-HT4 recep- such as infl ammatory bowel diseases, IBS, and enteric tor agonists (e.g. tegaserod) potentiate peristalsis, initi- infections21. ated by 5HT1 receptor stimulation, eases the abdomi- 5-HT7 receptors control body temperature, regu- nal pain and increases the number of bowel movements late sleep and circadian rhythms. Preclinical data also 8 and decreses stool consistency . support the antidepressant actions of 5-HT7 receptor 5-HT4 receptor agonists (e.g. tegaserod) have been antagonists, but clinical effi cacy has not been yet esta- associated with cardiovascular adverse events proba- blished. Other evidences have implicated the 5-HT7 bly because of changes in the function of the cardiac receptor in learning and memory. Blockade of this re- hERG (human Ether-à-go-go Related Gene) potas- ceptor may be benefi cial against schizophrenia-like cog- sium channel. New-generation 5-HT4 receptor ago- nitive defi cits; other possible indications include pain, nists (e.g. prucalopride, velusetrag) are devoid of these epilepsy, migraine, and autism spectrum disorders22. adverse eff ects9. Th e 5-HT5A receptors are Gi/Go coupled proteins, SELECTIVE SEROTONIN REUPTAKE that inhibit the manufacture of the cAMP intracellular INHIBITORS (SSRIS) signaling molecule10. Despite the fact that humans have also a gene coding for the 5-HT5B subtype, the 5-HT5A Selective serotonin reuptake inhibitors (SSRIs) modu- subtype is the only one expressed in the human brain. lates serotonin levels and are one of the most used class Th is is because the coding sequence of 5-HT5B subtype of antidepressants, probably because they induce fewer is interrupted by stop codons, making the gene non- adverse eff ects than classical tricyclic agents23. SSRI 11 functional . Th e 5-HT5 receptors have not been exten- generics include fl uoxetine, fl uvoxamine, citalopram, sively characterized pharmacologically. LSD (lysergic sertraline, paroxetine and escitalopram. acid diethylamide) appears to act as a partial agonist at the 5-HT5A receptor. Another partial agonists are va- lerian extract and valerenic acid12. However, few highly 6 Modern Medicine | 2017, Vol. 24, No. 1 Pharmacodynamics of Serotonin. Emphasis on 5HT-3 Antagonists and SSRI Medication (II) MECHANISM OF ACTION In addition, SSRIs in higher dosage than recom- mended worsen preexistent suicidal ideation36. Epi- SSRIs inhibit the reuptake of serotonin and, as a result, demiologic studies show that SSRI treatment is linked serotonin lasts longer in the synaptic cleft and can sti- with upper gastrointestinal bleeding; other bleeding mulate several times the presynaptic and postsynaptic sites has been less commonly reported, as has a pos- receptors. Th e supposed mechanism of the antidepres- sibly increased risk of bleeding associated with sur- sive eff ect is the serotonergic reinforcement. gical procedures37. Patients who take both SSRI and Serotonergic reinforcement does not take place blood thinners and/or NSAIDs (nonsteroidal anti-in- immediately after the initiation of treatment, as increa- fl ammatory drugs), as well as those suff ering from liver sed serotonin levels stimulate 5-HT1A autoreceptors as failure or cirrhosis are more vulnerable
Recommended publications
  • Corporate Release No 485 12 December 2012 FDA Accepts

    Corporate Release No 485 12 December 2012 FDA Accepts

    H. Lundbeck A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail [email protected] DK-2500 Valby, Copenhagen Fax +45 36 43 82 62 www.lundbeck.com CVR number: 56759913 Corporate Release No 485 12 December 2012 FDA accepts Takeda and Lundbeck’s filing for review of Brintellix (vortioxetine) for the treatment of major depression FDA has determined that the New Drug Application filed in October 2012 is sufficiently complete to permit a substantive review Upon the acceptance of the filing by the FDA, Lundbeck is to receive a milestone of USD 50 million (approximately DKK 285 million) from Takeda H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) has accepted the submission of a New Drug Application (NDA) for BrintellixTM (vortioxetine) for the treatment of major depressive disorder (MDD) in adult patients. Brintellix (pronounced “brin′-tel-ix”) is the proposed global trade name for vortioxetine. According to the timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the NDA is targeted for completion by 2 October, 2013. The NDA includes positive data from six short-term studies and one long-term maintenance study. The vortioxetine global clinical development program included more than 7,500 individuals aged 18 to 88 years old exposed to the drug. Major depression, often referred to as depression, is a common, debilitating illness affecting around 15 million Americans and 121 million people worldwide. Depression was the third leading contributor to the global burden of disease in 2004 and is projected to be the leading contributor to the worldwide burden of disease by 2030.
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders

    New Developments in Prokinetic Therapy for Gastric Motility Disorders

    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
  • Serotonin Receptors and Their Role in the Pathophysiology and Therapy of Irritable Bowel Syndrome

    Serotonin Receptors and Their Role in the Pathophysiology and Therapy of Irritable Bowel Syndrome

    Tech Coloproctol DOI 10.1007/s10151-013-1106-8 REVIEW Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome C. Stasi • M. Bellini • G. Bassotti • C. Blandizzi • S. Milani Received: 19 July 2013 / Accepted: 2 December 2013 Ó Springer-Verlag Italia 2013 Abstract Results Several lines of evidence indicate that 5-HT and Background Irritable bowel syndrome (IBS) is a functional its receptor subtypes are likely to have a central role in the disorder of the gastrointestinal tract characterized by pathophysiology of IBS. 5-HT released from enterochro- abdominal discomfort, pain and changes in bowel habits, maffin cells regulates sensory, motor and secretory func- often associated with psychological/psychiatric disorders. It tions of the digestive system through the interaction with has been suggested that the development of IBS may be different receptor subtypes. It has been suggested that pain related to the body’s response to stress, which is one of the signals originate in intrinsic primary afferent neurons and main factors that can modulate motility and visceral per- are transmitted by extrinsic primary afferent neurons. ception through the interaction between brain and gut (brain– Moreover, IBS is associated with abnormal activation of gut axis). The present review will examine and discuss the central stress circuits, which results in altered perception role of serotonin (5-hydroxytryptamine, 5-HT) receptor during visceral stimulation. subtypes in the pathophysiology and therapy of IBS. Conclusions Altered 5-HT signaling in the central ner- Methods Search of the literature published in English vous system and in the gut contributes to hypersensitivity using the PubMed database.
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology

    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
  • Gastroparesis - Recent Advances in the Pathophysiology and Treatment

    Gastroparesis - Recent Advances in the Pathophysiology and Treatment

    ICDM 2015 Gastroparesis - Recent advances in the pathophysiology and treatment - Department of Internal Medicine, College of Medicine, St. Paul’s hospital, The Catholic University of Korea, Seoul, Korea Jung Hwan Oh 2015-10-16 Etiology . Idiopathic -- 40% . Diabetes mellitus -- 30% . Postsurgical (Gastrectomy/fundoplication) . Connective tissue disease . Hypothyroidism . Malignancy . Provocation drugs 2/46 . End-stage renal disease Number of people with diabetes (20-79 years), 2013 International Diabetes Federation: Diabetes Atlas 6th ed. 2013 3/46 Prevalence of DM in Korea % 15 11.9 10.1 10 8.6 5 0 2001 2010 2013 4/46 (>30 yo) Prevalence of GI symptoms in DM in Korea 15 % 13.2 11.2 10 8.2 7.1 5 N/V bloating dyspepsia heartburn 5/46 Oh JH, Choi MG et al. Korean J Intern Med 2009 Contents . Gastroparesis? . Prevalence . Recent advances in pathophysiology & treatment . Summary 6/46 What is gastroparesis? Delayed Absence of Symptoms gastric obstruction emptying 7/46 Classification . Mild gastroparesis . Moderate : Compensated gastroparesis – moderate symptoms with use of daily medications, maintain nutrition with dietary adjustments . Severe : Gastric failure – refractory symptoms that are not controlled, – inability to maintain oral nutrition Stanghellini V. Gut. 2014 8/46 Typical symptoms? . Nausea, vomiting . Abdominal discomfort . Early satiety . Postprandial fullness . Bloating 9/46 Gastroparesis: separate entity or just a part of FD? FD GP dus=bad gastro=stomach pa’ resis=incomplete paralysis pepto=digestion FD: Functional dyspepsia, GP: Gastroparesis Stanghellini V. Gut. 2014 Diagnosis . Scintigraphy . Wireless motility capsule (WMC) . Breath testing : 13C breath testing using otanoic acid, acetate or spirulina 11/46 Gastric Emptying Scintigraphy 20 Min 40 60 80 120 Delayed gastric emptying as greater than 60% retention at 2 hours and/or 10% at 4 hours 12/46 Consensus recommendations for gastric emptying scintigraphy .
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety

    New Treatment Options for Chronic Constipation: Mechanisms, Efficacy and Safety

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE CHRONIC CONSTIPATION – CHALLENGES AND REMEDIES provided by Crossref New treatment options for chronic constipation: Mechanisms, efficacy and safety Michael Camilleri MD M Camilleri. New treatment options for chronic constipation: De nouvelles options thérapeutiques contre la Mechanisms, efficacy and safety. Can J Gastroenterol constipation chronique : leurs mécanismes, leur 2011;(Suppl B):29B-35B. efficacité et leur innocuité The present review has several objectives, the first of which is to review the pharmacology and selectivity of serotonergic agents to La présente analyse comporte plusieurs objectifs, le premier étant de contrast the older serotonergic agents (which were withdrawn because réviser la pharmacologie et la sélectivité des sérotoninergiques pour of cardiac or vascular adverse effects) with the newer generation sero- comparer les anciens sérotoninergiques (retirés du marché en raison de tonin receptor subtype 4 agonists. Second, the chloride ion secret- leurs effets cardiaques ou vasculaires) avec les agonistes de récepteurs agogues that act through the guanylate cyclase C receptor are appraised de la sérotonine de sous-type 4 de nouvelle génération. En deuxième and their pharmacology is compared with the approved medication, lieu, les sécrétagogues des ions chlorures qui agissent par le récepteur lubiprostone. Third, the efficacy and safety of the application of bile du guanylatecyclase C sont évalués, et leur pharmacologie est com- acid modulation to treat constipation are addressed. The long-term parée avec celle du lubiprostone, un médicament approuvé. En studies of surgically induced excess bile acid delivery to the colon are troisième lieu, l’efficacité et l’innocuité de l’application de la modula- reviewed to ascertain the safety of this therapeutic approach.
  • Gastroparesis: 2014

    Gastroparesis: 2014

    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
  • G Protein-Coupled Receptors

    G Protein-Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
  • G Protein‐Coupled Receptors

    G Protein‐Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
  • GPCR/G Protein

    GPCR/G Protein

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
  • Comparative Transcriptome Profiling of the Human and Mouse Dorsal Root

    Comparative Transcriptome Profiling of the Human and Mouse Dorsal Root

    Research Paper Comparative transcriptome profiling of the human and mouse dorsal root ganglia: an RNA-seq–based resource for pain and sensory neuroscience research a,b a a a a a 07/20/2018 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3mH5nK33R3Qh4f27oe7zFUUf7ZAUK5aCsyqAeT54jiDxP7ZjumT3TrA== by https://journals.lww.com/pain from Downloaded Pradipta Ray , Andrew Torck , Lilyana Quigley , Andi Wangzhou , Matthew Neiman , Chandranshu Rao , Downloaded Tiffany Lama, Ji-Young Kima, Tae Hoon Kimb, Michael Q. Zhangb, Gregory Dussora, Theodore J. Pricea,* from https://journals.lww.com/pain Abstract Molecular neurobiological insight into human nervous tissues is needed to generate next-generation therapeutics for neurological disorders such as chronic pain. We obtained human dorsal root ganglia (hDRG) samples from organ donors and performed RNA- sequencing (RNA-seq) to study the hDRG transcriptional landscape, systematically comparing it with publicly available data from by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3mH5nK33R3Qh4f27oe7zFUUf7ZAUK5aCsyqAeT54jiDxP7ZjumT3TrA== a variety of human and orthologous mouse tissues, including mouse DRG (mDRG). We characterized the hDRG transcriptional profile in terms of tissue-restricted gene coexpression patterns and putative transcriptional regulators, and formulated an information-theoretic framework to quantify DRG enrichment. Relevant gene families and pathways were also analyzed, including transcription factors, G-protein-coupled receptors, and ion channels. Our analyses reveal an hDRG-enriched protein-coding gene set (;140), some of which have not been described in the context of DRG or pain signaling. Most of these show conserved enrichment in mDRG and were mined for known drug–gene product interactions. Conserved enrichment of the vast majority of transcription factors suggests that the mDRG is a faithful model system for studying hDRG, because of evolutionarily conserved regulatory programs.